These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Identification of two immune subtypes in osteosarcoma based on immune gene sets. Yang M; Cao Y; Wang Z; Zhang T; Hua Y; Cai Z Int Immunopharmacol; 2021 Jul; 96():107799. PubMed ID: 34162161 [TBL] [Abstract][Full Text] [Related]
23. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739 [TBL] [Abstract][Full Text] [Related]
24. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes. Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032 [TBL] [Abstract][Full Text] [Related]
25. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes. Song YJ; Xu Y; Deng C; Zhu X; Fu J; Chen H; Lu J; Xu H; Song G; Tang Q; Wang J Front Immunol; 2021; 12():623762. PubMed ID: 33959121 [TBL] [Abstract][Full Text] [Related]
26. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma. Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y Front Immunol; 2021; 12():806189. PubMed ID: 35095893 [TBL] [Abstract][Full Text] [Related]
27. TYROBP, TLR4 and ITGAM regulated macrophages polarization and immune checkpoints expression in osteosarcoma. Liang T; Chen J; Xu G; Zhang Z; Xue J; Zeng H; Jiang J; Chen T; Qin Z; Li H; Ye Z; Nie Y; Liu C; Zhan X Sci Rep; 2021 Sep; 11(1):19315. PubMed ID: 34588497 [TBL] [Abstract][Full Text] [Related]
29. Development of a Risk Model and Genotyping Patterns Based on Disulfidptosis-Related lncRNAs to Predict Prognosis and Immune Landscape in Osteosarcoma. Zhang K; Lu S; Jiang M; Zou X; Chen C; Lan Y; Zhao H; Ma R; Yan H Front Biosci (Landmark Ed); 2024 May; 29(5):193. PubMed ID: 38812298 [TBL] [Abstract][Full Text] [Related]
30. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level. Wang W; Ren S; Wang Z; Zhang C; Huang J Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070 [TBL] [Abstract][Full Text] [Related]
31. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma. Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203 [No Abstract] [Full Text] [Related]
32. High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC. Oh MS; Anker JF; Chae YK Cancer Treat Res Commun; 2021; 27():100317. PubMed ID: 33711637 [TBL] [Abstract][Full Text] [Related]
33. Immune infiltration profiling in gastric cancer and their clinical implications. Ren F; Zhao Q; Zhao M; Zhu S; Liu B; Bukhari I; Zhang K; Wu W; Fu Y; Yu Y; Tang Y; Zheng P; Mi Y Cancer Sci; 2021 Sep; 112(9):3569-3584. PubMed ID: 34251747 [TBL] [Abstract][Full Text] [Related]
34. PNOC Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology. Chen Z; Yu M; Yan J; Guo L; Zhang B; Liu S; Lei J; Zhang W; Zhou B; Gao J; Yang Z; Li X; Zhou J; Fan J; Ye Q; Li H; Xu Y; Xiao Y Front Immunol; 2021; 12():647209. PubMed ID: 33841428 [TBL] [Abstract][Full Text] [Related]
35. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma. Liu D; Yang X; Wu X Front Immunol; 2021; 12():663495. PubMed ID: 34025664 [TBL] [Abstract][Full Text] [Related]
36. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas. Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942 [TBL] [Abstract][Full Text] [Related]
37. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis. Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C Front Immunol; 2021; 12():818492. PubMed ID: 35095920 [TBL] [Abstract][Full Text] [Related]
38. Patrolling monocytes inhibit osteosarcoma metastasis to the lung. Chen T; Zhao L Aging (Albany NY); 2020 Nov; 12(22):23004-23016. PubMed ID: 33203789 [TBL] [Abstract][Full Text] [Related]
39. Identification of TNFRSF1A as a potential biomarker for osteosarcoma. Zhang Y; Liu K; Wang J Cancer Biomark; 2024; 39(4):299-312. PubMed ID: 38250759 [TBL] [Abstract][Full Text] [Related]
40. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients. Li LQ; Zhang LH; Zhang Y; Lu XC; Zhang Y; Liu YK; Khader MA; Jia-Wen ; Tao-Liu ; Li JZ Aging (Albany NY); 2020 Nov; 12(22):22906-22926. PubMed ID: 33203792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]